Evidence map›Paper›PMID 25956133›Full record

ArticleOrphanet journal of rare diseases2015

Biological parameters predictive of percent dense red blood cell decrease under hydroxyurea.

Marie Georgine Rakotoson, Gaetana Di Liberto, Etienne Audureau, Anoosha Habibi, Christine Fauroux, Sanam Khorgami, Anne Hulin, Sylvain Loric, France Noizat-Pirenne, Frédéric Galacteros and 1 more

Abstract readClinical Study
In one paragraph

Article in Orphanet journal of rare diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. SIRT1 activates the expression of fetal hemoglobin genes.American journal of hematology · 2017
    Article
  6. Sickle cell disease biochip: a functional red blood cell adhesion assay for monitoring sickle cell disease.Translational research : the journal of laboratory and clinical medicine · 2016
    Article
  7. 2015 Clinical trials update in sickle cell anemia.American journal of hematology · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marie Georgine RakotosonInstitut Mondor de Recherche Biomédicale, Unité 955, Equipe 2: Transfusion et Maladies du Globule Rouge, Université Paris-Est Créteil, Créteil, France. rmariegeorgine@yahoo.com.
Gaetana Di LibertoInstitut Mondor de Recherche Biomédicale, Unité 955, Equipe 2: Transfusion et Maladies du Globule Rouge, Université Paris-Est Créteil, Créteil, France. gaetanadiliberto@yahoo.fr.
Etienne AudureauService de Santé Publique, Hôpital Henri-Mondor, APHP, LIC EA4393, Université Paris-Est Créteil, Créteil, France. etienne.audureau@gmail.com.
Anoosha HabibiCentre de Référence des Syndromes Drépanocytaires Majeurs, Hôpital Henri-Mondor, APHP, Université Paris-Est Créteil, 51, avenue du Mal-de-Lattre-de-Tassigny, 94010, Créteil Cedex, France. anoosha.habibi@aphp.fr.
Christine FaurouxCentre de Référence des Syndromes Drépanocytaires Majeurs, Hôpital Henri-Mondor, APHP, Université Paris-Est Créteil, 51, avenue du Mal-de-Lattre-de-Tassigny, 94010, Créteil Cedex, France. christine.fauroux@aphp.fr.
Sanam KhorgamiInstitut Mondor de Recherche Biomédicale, Unité 955, Equipe 2: Transfusion et Maladies du Globule Rouge, Université Paris-Est Créteil, Créteil, France. sanam_khmi@yahoo.com.
Anne HulinLaboratoire de Pharmacologie, APHP, Hôpital Henri-Mondor, Université Paris Est-Créteil, Créteil, France. anne.hulin@aphp.fr.
Sylvain LoricLaboratoire de Biochimie et Génétique, Hôpital Henri-Mondor, Créteil, France. sylvain.loric@aphp.fr.
France Noizat-PirenneInstitut Mondor de Recherche Biomédicale, Unité 955, Equipe 2: Transfusion et Maladies du Globule Rouge, Université Paris-Est Créteil, Créteil, France. france.noizat-pirenne@efs.sante.fr.
Frédéric GalacterosInstitut Mondor de Recherche Biomédicale, Unité 955, Equipe 2: Transfusion et Maladies du Globule Rouge, Université Paris-Est Créteil, Créteil, France. frederic.galacteros@aphp.fr.
Pablo BartolucciInstitut Mondor de Recherche Biomédicale, Unité 955, Equipe 2: Transfusion et Maladies du Globule Rouge, Université Paris-Est Créteil, Créteil, France. pablo.bartolucci@aphp.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDense red blood cells (DRBCs) are associated with chronic clinical manifestations of sickle-cell-disease (SCD). Hydroxyurea (HU) decreases the percent (%) DRBCs, thereby improving its therapeutic benefits, especially the prevention of SCD clinical complications, but parameters influencing %DRBCs remain unknown. The purpose of this study was to determine predictive biological parameters of %DRBC decline under HU.

methodsFactors affecting the %DRBC decrease in SCD patients HU-treated for ≥6 months were analyzed. Biological parameters and the %DRBCs were determined before starting HU and after ≥6 months of HU intake. Bivariate analyses evaluated the impact of each biological parameter variation on %DRBC changes under treatment. Multivariate analyses assessed the correlations between the decreased %DRBCs and biological parameters.

resultsThe %DRBCs declined by 40.95% after ≥6 months on HU. That decrease was associated with less hemolysis, however in several analyses on this group of patients we did not find a statistically significant correlation between decrease in %DRBCs and increase in HbF. Initial %DRBC values were the most relevant parameter to predict %DRBC decline.

conclusionOur results strengthen the known HU efficacy in SCD management statistically independently of the classical HbF biological response. Decreasing %DRBCs is essential to limiting chronic SCD symptoms related to DRBCs and predictive factors might help prevent those manifestations. The results of this study provide new perspectives on indication for HU use, i.e., to prevent SCD-induced organ damage.

Indexed as

AdultAnemia, Sickle CellErythrocytes, AbnormalFemaleFetal HemoglobinHumansHydroxyureaMaleFetal HemoglobinHydroxyurea

Identifiers

PMID25956133
PMCPMC4430928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.